Selecting and Using the Appropriate Influenza Vaccine for Each Individual

Sekiya, Toshiki; Ohno, Marumi; Nomura, Naoki; Handabile, Chimuka; Shingai, Masashi; Jackson, David C.; Brown, Lorena E.; Kida, Hiroshi

doi:10.3390/v13060971

Cited by 27 publications

(15 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, we evaluated the immunogenicity of a single inoculation of WPV and SV in mice and macaques. The results indicated that WPV was superior to SV in priming naïve animals and protecting against homologous virus infection [ 11 , 12 , 13 ], which reproduces the concern with SV in humans. We also showed that the priming potency of WPV may be linked to its ability to significantly activate the maturation of antigen-presenting cells (APCs) through the efficient delivery of viral RNA into the cells [ 13 ].…”

Section: Introductionmentioning

confidence: 96%

“…Current influenza vaccines are of two types: live attenuated influenza vaccines and inactivated influenza vaccines (IIV) such as split vaccines (SV), whole virus particle vaccines (WPV), and subunit vaccines [ 11 ]. SV consists of viral components that are the products of purified virions that are disrupted with ether or detergent, while subunit vaccine undergoes an additional purification step for the further enrichment of HA or NA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection

et al. 2022

Self Cite

View full text Add to dashboard Cite

Despite the use of vaccines, seasonal influenza remains a risk to public health. We previously proposed the inactivated whole virus particle vaccine (WPV) as an alternative to the widely used split vaccine (SV) for the control of seasonal and pandemic influenza based on the superior priming potency of WPV to that of SV. In this study, we further examined and compared the immunological potency of monovalent WPV and SV of A/California/7/2009 (X-179A) (H1N1) pdm09 (CA/09) to generate immune responses against heterologous viruses, A/Singapore/GP1908/2015 (IVR-180) (H1N1) pdm09 (SG/15), and A/duck/Hokkaido/Vac-3/2007 (H5N1) (DH/07) in mice. Following challenge with a lethal dose of heterologous SG/15, lower virus titer in the lungs and milder weight loss were observed in WPV-vaccinated mice than in SV-vaccinated ones. To investigate the factors responsible for the differences in the protective effect against SG/15, the sera of vaccinated mice were analyzed by hemagglutination-inhibition (HI) and neuraminidase-inhibition (NI) assays to evaluate the antibodies induced against viral hemagglutinin (HA) and neuraminidase (NA), respectively. While the two vaccines induced similar levels of HI antibodies against SG/15 after the second vaccination, only WPV-vaccinated mice induced significantly higher titers of NI antibodies against the strain. Furthermore, given the significant elevation of NI antibody titers against DH/07, an H5N1 avian influenza virus, WPV was also demonstrated to induce NA-inhibiting antibodies that recognize NA of divergent strains. This could be explained by the higher conservation of epitopes of NA among strains than for HA. Taking these findings together, NA-specific antibodies induced by WPV may have contributed to better protection from infection with heterologous influenza virus SG/15, compared with SV. The present results indicate that WPV is an effective vaccine for inducing antibodies against both HA and NA of heterologous viruses and may be a useful vaccine to conquer vaccine strain mismatch.

show abstract

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The WHO vaccine safety basics manual ( 88 ) and Sekiya et al. ( 89 ) thoroughly discussed the properties and differences between the different vaccine types. Inactivated WVVs use whole viruses in immunization and may induce strong immune responses.…”

Section: Evolution Of Influenza Vaccinesmentioning

confidence: 99%

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

2022

View full text Add to dashboard Cite

Flu, a viral infection caused by the influenza virus, is still a global public health concern with potential to cause seasonal epidemics and pandemics. Vaccination is considered the most effective protective strategy against the infection. However, given the high plasticity of the virus and the suboptimal immunogenicity of existing influenza vaccines, scientists are moving toward the development of universal vaccines. An important property of universal vaccines is their ability to induce heterosubtypic immunity, i.e., a wide immune response coverage toward different influenza subtypes. With the increasing number of studies and mounting evidence on the safety and efficacy of recombinant influenza vaccines (RIVs), they have been proposed as promising platforms for the development of universal vaccines. This review highlights the current progress and advances in the development of RIVs in the context of heterosubtypic immunity induction toward universal vaccine production. In particular, this review discussed existing knowledge on influenza and vaccine development, current hemagglutinin-based RIVs in the market and in the pipeline, other potential vaccine targets for RIVs (neuraminidase, matrix 1 and 2, nucleoprotein, polymerase acidic, and basic 1 and 2 antigens), and deantigenization process. This review also provided discussion points and future perspectives in looking at RIVs as potential universal vaccine candidates for influenza.

show abstract

“…Recently, recombinant HA vaccines were approved for influenza prevention [ 27 ]. This type of vaccine is manufactured by HA protein expression in the baculovirus–insect cell system.…”

Section: Introductionmentioning

confidence: 99%

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

et al. 2022

View full text Add to dashboard Cite

The seasonal flu vaccine is, essentially, the only known way to prevent influenza epidemics. However, this approach has limited efficacy due to the high diversity of influenza viruses. Several techniques could potentially overcome this obstacle. A recent first-in-human study of a chimeric hemagglutinin-based universal influenza virus vaccine demonstrated promising results. The coronavirus pandemic triggered the development of fundamentally new vaccine platforms that have demonstrated their effectiveness in humans. Currently, there are around a dozen messenger RNA and self-amplifying RNA flu vaccines in clinical or preclinical trials. However, the applicability of novel approaches for a universal influenza vaccine creation remains unclear. The current review aims to cover the current state of this problem and to suggest future directions for RNA-based flu vaccine development.

show abstract

Selecting and Using the Appropriate Influenza Vaccine for Each Individual

Cited by 27 publications

References 117 publications

Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection

Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

Contact Info

Product

Resources

About